The FDA granted accelerated approval to Lunsumio VELO for adults with relapsed/refractory follicular lymphoma after two or more prior treatments. The U.S. Food and Drug Administration (FDA) has ...

What Is Lunsumio Velo, and Why Does It Matter? Lunsumio Velo (mosunetuzumab-axgb) is a new under-the-skin (subcutaneous) injection version of the anticancer medicine Lunsumio intravenous infusion. The ...

The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...

(MENAFN- GlobeNewsWire - Nasdaq) BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Secura Bio, Inc. ( ), an integrated pharmaceutical company maximizing commercial outcomes for oncology ...

Detailed price information for Corvus Pharma Com (CRVS-Q) from The Globe and Mail including charting and trades.

The going has been strong for Regeneron Pharmaceuticals REGN over the past six months. Shares of this biotech giant have ...

Radiation therapy has been a foundation of cancer care for more than a century. From early X-ray machines to today’s ...

About Secura Bio, Inc. Secura Bio is an integrated, commercial-stage pharmaceutical company dedicated to the worldwide development and commercialization of impactful oncology therapies for physicians ...

Explore innovative treatments for relapsed follicular lymphoma, focusing on novel therapies that enhance patient outcomes and ...

Shared decision-making—balancing clinical data with the patient's personal, logistical, and risk-tolerance factors—is ...

Lunsumio Velo is supplied as a ready-to-use, preservative-free solution in single-dose vials containing 5mg/0.5mL and 45mg/mL.

Trial data on epcoritamab plus rituximab-lenalidomide, a novel CELMoD agent, late-line CAR-T cell therapy, and selecting ...